Back to search

University of British Columbia

Venturing into the undruggable – a quest from STAT3 to TrkA inhibition in anticancer drug discovery

Abstract

dc:description

Signal transducer and activator of transcription 3 (STAT3) is widely recognized as a prominent anticancer drug target, yet its complex signaling and limited “druggability” present major challenges for developing potent and selective inhibitors that directly target STAT3. Recent advances in thermal shift assays like differential scanning fluorimetry (DSF) and Cellular thermal shift assay (CETSA) have expanded the toolkit for STAT3 drug discovery by enabling the identification and validation of inhibitors that directly bind STAT3 in biochemical and cellular conditions, respectively. My doctoral work proposed the execution of an integrated drug discovery funnel using thermal shift assays alongside phenotypic STAT3 assays, aiming to enable the discovery and optimization of direct STAT3 inhibitors. To this end, the protein thermal shift assay (PTSA) was adapted as a supportive screening and validation tool linking DSF and CETSA, facilitating the assessment of small molecules for their interaction with STAT3 in biochemical settings. I introduce a target engagement-focused screening and optimization pipeline combining these chemical biology techniques with other STAT3 inhibition assays. From a STAT3 DSF high-throughput screen, to complementary and orthogonal assays, I identified a series of compounds that appeared to stabilize STAT3 towards thermal aggregation and moderately inhibited cellular STAT3 activity. However, thoroughly evaluating these compounds in auxiliary and orthogonal assays illuminated their high-affinity for tropomyosin receptor kinase A (TrkA) and other kinase targets, disputing them as direct STAT3 antagonists. Structural activity relationship studies were then employed to further refine inhibitor binding for TrkA, a prominent target in rare NTRK1 fusion-positive cancers. Applying a similar target engagement-inspired approach, I optimized this inhibitor series to identify compounds with improved binding affinity and selectivity towards TrkA. Cellular activity in TrkA cancer models was evaluated with top compounds, including PI-15, which demonstrated successful target-engagement in cell lysate CETSA and potently inhibited TPM3-TrkA phosphorylation in TrkA fusion-positive colon cancer cells. Further lead modifications yielded compound PI-15R, a metabolically stable, cell-permeable and potent Trk kinase inhibitor with single-digit nanomolar IC50 values. Overall, identifying a promising kinase inhibitor through comprehensive validation screening approaches, this study highlights the value of rigorous target engagement validation early in the drug discovery pipeline.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Pharmaceutical Sciences
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Iliev, Petar Ilianov
Contributors dc:contributor
  • Page, Brent D. G.

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/89152

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Iliev, Petar Ilianov. Venturing into the undruggable – a quest from STAT3 to TrkA inhibition in anticancer drug discovery. doctoral thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/89152